The study, led by Ali H. Duzkalir and Selcuk Peker of Koc University Hospital in Istanbul, pooled data from twelve institutions spanning the United States, Canada, Europe, the Middle East, and East Asia. Because male breast cancer accounts for less than one percent of all breast cancer cases, and because brain metastases arise in only a subset of those patients, no single center could ever accumulate enough cases to draw meaningful conclusions. By aggregating decades of experience from flagship radiosurgery programs, including the University of Pittsburgh Medical Center, the University of Virginia, NYU Langone, Na Homolce Hospital in Prague, Taipei Veterans General Hospital, and Sheba Medical Center in Israel, the researchers assembled a cohort large enough to interrogate with modern statistical tools. Nineteen patients carrying a total of 185 individually treated lesions formed the final analytical dataset.

The technical architecture of the analysis deserves attention, because it reflects how radiosurgery outcomes are increasingly evaluated in the era of big-data oncology. Rather than treating each patient as a single independent data point, the team used generalized estimating equations with robust variance estimation, a method that correctly accounts for the fact that one patient may contribute several lesions whose outcomes are statistically correlated. Overall survival was estimated with Kaplan-Meier curves, the standard approach for handling censored follow-up times. Changes in neurological symptoms before and after treatment were tested with McNemar’s exact test, a paired analysis suited to before-and-after binary outcomes in a small cohort. To identify which radiation dose characteristics predicted treatment failure, the investigators turned to receiver operating characteristic analysis, which measures how well a continuous variable, such as tumor volume, discriminates between lesions that recur and those that do not.

The headline finding is the crude local control rate of 97.3 percent, meaning that nearly every irradiated tumor stopped growing after a single radiosurgical session. For context, brain metastases from many other cancer types often recur locally in ten to twenty percent of treated lesions even at experienced centers, so a failure rate below three percent is remarkable. The median age of the patients at the time of radiosurgery was 59.0 years, and the cohort’s median overall survival reached 28.0 months, a figure that compares favorably with published survival data for breast cancer brain metastases more broadly, where whole-brain radiation therapy cohorts frequently show far shorter survival.

Perhaps the most clinically consequential result concerns what happened outside the brain. Patients whose systemic disease, meaning cancer elsewhere in the body, was under control at the time of radiosurgery lived a median of 40.0 months, compared with just 22.0 months for those with uncontrolled systemic disease, a difference that reached statistical significance at p equals 0.032. This pattern echoes a growing body of evidence from female breast cancer cohorts, including the SYBRA study published in npj Breast Cancer in 2024, which found that systemic disease status strongly influences central nervous system outcomes after radiosurgery. The message for clinicians is unambiguous: the brain is only one battlefield, and survival in oligometastatic disease is ultimately governed by whether the cancer can be contained throughout the body.

On the dosimetric side, the study identified target volume as the single most important predictor of both treatment failure and radiation toxicity. Receiver operating characteristic analysis showed that lesion volume significantly discriminated between controlled and failed lesions, with an optimal threshold of 0.98 cubic centimeters, roughly a sphere just over a centimeter in diameter. Lesions smaller than this threshold were far more likely to be permanently controlled. The same variable independently predicted adverse radiation effects on multivariable analysis at p equals 0.013, confirming a principle well established in the radiosurgery literature: the larger the target, the harder it becomes to deliver an ablative dose without injuring adjacent brain tissue, because dose falloff is finite and larger volumes inevitably expose more normal parenchyma.

The safety and neurological data add an important human dimension. Before treatment, 63.2 percent of patients carried a neurological symptom burden attributable to their brain metastases, ranging from headaches and seizures to focal deficits. After radiosurgery, that figure fell to 26.3 percent, a statistically significant improvement at p equals 0.016. Equally important, the median Karnofsky Performance Status, a standard zero-to-one-hundred scale of functional independence used across oncology, remained stable over follow-up. In a population where brain-directed treatment can sometimes trade cognitive function for tumor control, the combination of symptom relief and preserved performance status is exactly the profile clinicians hope to see.

Why does this matter beyond the nineteen patients studied? Male breast cancer is biologically distinct in several respects. Population-based analyses of SEER registry data and recent reviews have shown that men are more often diagnosed at later stages, more frequently carry hormone receptor positive tumors, and may experience different metastatic patterns than women. Molecular studies have even documented subtype conversion in metastatic lesions, meaning the tumor’s receptor profile can shift between the primary breast tumor and its brain deposits, complicating targeted therapy. Because men are typically excluded from breast cancer trials by design or by accident, evidence for their care is often extrapolated from female cohorts. This study provides direct, lesion-level evidence that the established practice parameters for stereotactic radiosurgery, developed and refined over decades largely in women, translate safely and effectively to men.

The findings also arrive at a moment of ferment in the field of brain metastasis management. Randomized trials comparing whole-brain radiation with radiosurgery are ongoing, and the rising use of antibody-drug conjugates and other potent systemic agents has raised new questions about combined treatment toxicity, including radiation necrosis risk highlighted in a 2026 systematic review in Neurosurgical Reviews. Against that backdrop, the current study anchors one corner of the evidence base: for men with breast cancer brain metastases, focused radiosurgery achieves near-total local control, shrinks the neurological symptom burden, and preserves function, provided that lesions are kept within the volume range where the technique excels.

The authors are careful about the limitations inherent to their design. A retrospective cohort of nineteen patients cannot establish causation, cannot capture every variable that influences survival, and cannot substitute for prospective registration. The study received no external funding, was approved by the Institutional Review Board of Koc University, and was conducted in accordance with the Declaration of Helsinki, with informed consent waived due to the de-identified, retrospective nature of the data. Yet in a disease so rare that even the largest single institutions may see one case every few years, the multicenter retrospective approach is not a compromise but the only realistic path forward. The study, published as volume 179, article 73 of the Journal of Neuro-Oncology on 9 September 2026, gives clinicians treating this overlooked population something they have never had before: numbers they can stand on.

Subject of Research: Stereotactic radiosurgery outcomes for brain metastases arising from male breast cancer

Article Title: Stereotactic radiosurgery for brain metastases from male breast cancer: a multicenter retrospective study

Article References: Duzkalir, A. H., Askeroglu, M. O., Yildirim, D. C., Marciniuk, K., Bernstein, K., Tos, S. M., Reyes, J. S., Liscak, R., Simonova, G., Sumi, T., Kano, H., Kilic, T., Kilic, D., Bowden, G. N., Shemesh, S. Z., Kaisman-Elbaz, T., Lee, C.-C., Yang, H.-C., Kutuk, T., … Peker, S. (2026). Stereotactic radiosurgery for brain metastases from male breast cancer: a multicenter retrospective study. Journal of Neuro-Oncology, 179(2), Article 73. https://doi.org/10.1007/s11060-026-05795-x

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05795-x

Keywords: male breast cancer, brain metastases, stereotactic radiosurgery, local control, overall survival, Gamma Knife, radiation oncology, neuro-oncology, target volume, adverse radiation effects, Karnofsky Performance Status, multicenter study

The research, led by Cristian Udovicich and senior author Arjun Sahgal, focused on a technique the team calls salvage conventionally fractionated Gamma Knife stereotactic radiotherapy, abbreviated SFGK. Unlike single-session stereotactic radiosurgery, which delivers one concentrated blast of radiation, conventional fractionation spreads the treatment over many small daily doses, in this case most often 50.4 Gy delivered in 28 fractions. The approach exploits a fundamental principle of radiobiology: dividing a dose into smaller increments spares normal tissue far more than it spares the tumor, because healthy cells are better at repairing sublethal radiation damage between treatments than many tumor cells are.

Between 2019 and 2024, twenty-six consecutive patients harboring forty-four recurrent tumors underwent the salvage procedure. The overwhelming majority of these lesions, thirty-four in total or roughly three-quarters of the cohort, were meningiomas, the tumors that arise from the meninges, the protective membranes enveloping the brain and spinal cord. Most of these meningiomas were not benign; twenty-eight of the thirty-four were classified as World Health Organization Grade 2, an atypical form known for its stubborn tendency to recur even after surgery and radiation. The remaining patients carried other primary non-glial tumors, a category that excludes the gliomas and glioblastomas that originate from brain support cells and dominate much of the neuro-oncology literature.

What makes the study remarkable is the sheer amount of radiation these patients had already received. The median interval between the original radiotherapy course and the salvage treatment was 50.4 months, meaning most patients had enjoyed roughly four years of disease control before their tumors returned. Once SFGK was delivered, the median cumulative prescription dose, calculated using the EQD2 metric, which converts any radiation schedule into the biologically equivalent dose of 2 Gy per fraction, reached a staggering 102.7 Gy for patients who had undergone one prior course. For context, that figure approaches the tolerance limits of normal brain tissue, a territory where most radiation oncologists fear to tread.

The investigators were acutely aware of this danger, and the study’s dosimetry reflects a deliberate balancing act. The median EQD2 dose accumulated by normal brain tissue was 99.2 Gy, uncomfortably close to the tumor dose itself. This proximity underscores why conventional fractionation was chosen: by stretching 50.4 Gy across 28 sessions, the technique spreads out the biological burden on healthy tissue and allows gradual repair, while the precision of the Gamma Knife Icon platform, which integrates cone-beam CT imaging for frameless stereotactic guidance, ensures the radiation conforms tightly to each lesion. Earlier work by the same group, published in the Journal of Neurosurgery in 2023, had reported the first evidence that fractionated Gamma Knife reirradiation was feasible; the new study extends that signal with a larger cohort and formal survival statistics.

The results exceeded what many in the field would have predicted for such heavily irradiated tissue. Local progression-free survival, the study’s primary endpoint, stood at 91.0 percent at twelve months and 75.1 percent at twenty-four months across all patients. For the meningioma subgroup specifically, the corresponding figures were 90.6 percent and 74.1 percent. Overall survival was even more striking: 96.2 percent of patients were alive at one year and 83.2 percent at two years. In a population whose tumors had already defied surgery and a full course of radiation, these numbers represent a meaningful extension of disease control, particularly for atypical meningiomas, which historically carry poor outcomes at recurrence.

Safety data, often the Achilles heel of reirradiation studies, proved encouraging. Only two patients, or 6.9 percent of the cohort, developed Grade 3 radionecrosis, the dreaded condition in which irradiated brain tissue dies and swells, sometimes requiring surgery or corticosteroid therapy. A single patient, 3.4 percent, experienced Grade 3 progressive intracranial hemorrhage. Crucially, no Grade 4 or Grade 5 events, the most severe toxicity categories, were observed at all. With a median follow-up of 18.1 months, the authors acknowledge that late toxicities can take years to fully declare themselves, but the early safety profile appears acceptable given the extraordinarily high cumulative doses involved.

The study arrives at a moment when options for recurrent meningioma are desperately limited. Surgery at recurrence is often incomplete because these tumors adhere to critical vessels and nerves, and drug development has struggled; even recent trials of radioligand therapies such as lutetium-177 DOTATATE, tested prospectively in surgery- and radiation-refractory meningioma, remain experimental. Alternative reirradiation approaches using proton beams or carbon ions have shown promise but demand infrastructure unavailable to most patients. Fractionated Gamma Knife, by contrast, leverages equipment already installed in major cancer centers worldwide, making SFGK a potentially scalable salvage strategy.

The Toronto team’s work also fits into a broader movement in radiation oncology to formalize the once-forbidden practice of reirradiation. Recent prospective studies have established conventionally fractionated dose constraints for reirradiating primary brain tumors in adults, and the American Radium Society has published appropriate use criteria for retreatment in head and neck cancers. The Sunnybrook experience now provides some of the strongest evidence yet that primary brain tumors, specifically, can tolerate a second radical course when delivered with stereotactic precision and fractionation. A related report in 2025 documented even a third course of radical-intent conformal radiation in selected patients, suggesting the ceiling on cumulative dose may be higher than traditionally assumed when treatments are spaced and planned carefully.

For the patients whose atypical meningiomas had returned after years of remission, the study offers something that has long been in short supply: a well-tolerated option that meaningfully delays progression. The authors caution that their findings come from a retrospective single-institution series of twenty-six patients, and that longer follow-up will be needed to confirm durability and capture late toxicity. Yet the central conclusion stands on firm ground within those limits. Delivered in conventionally fractionated form on a modern frameless Gamma Knife platform, salvage reirradiation is feasible, achieves durable local control, and produces few serious adverse events, even when cumulative doses approach one hundred grays. For a field where recurrent, previously irradiated tumors have often meant palliative care alone, that is a result worth celebrating.

Subject of Research: Salvage fractionated Gamma Knife reirradiation for recurrent primary non-glial brain tumors

Article Title: Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors

Article References: Udovicich, C., Tseng, C.-L., Detsky, J., Chen, H., Dinakaran, D., Soliman, H., Zeng, K. L., Ruschin, M., Yeboah, C., Holden, L., Atenafu, E. G., & Sahgal, A. (2026). Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors. Journal of Neuro-Oncology, 179(3), Article 88. https://doi.org/10.1007/s11060-026-05757-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05757-3

Keywords: Gamma Knife, reirradiation, meningioma, brain tumors, stereotactic radiotherapy, radiation necrosis, local control, radionecrosis, WHO Grade 2 meningioma, fractionated stereotactic radiotherapy, salvage therapy, neuro-oncology

The context matters enormously. Colorectal cancer is one of the most common malignancies worldwide, and the liver is its most frequent destination for metastatic spread. Roughly a quarter to a third of patients already have distant metastases at diagnosis, and another half or more will develop them during the course of their illness. For a carefully defined subgroup, those with so-called oligometastatic disease, typically fewer than five tumours in no more than two organs, aggressive local treatment with curative intent can produce prolonged disease control and even long-term survival. Surgical resection remains the gold standard, delivering local control rates above 90 percent and five-year survival between 35 and 60 percent. But not every patient is a surgical candidate, and for those who are not, the field has lacked rigorous comparative data to guide the choice between thermal ablation and ablative radiation.

Microwave ablation, or MWA, works by inserting a needle-like probe directly into the tumour, usually under general anaesthesia and real-time ultrasound guidance. Electromagnetic waves at microwave frequencies agitate water molecules within the tissue, generating frictional heat that coagulates and destroys the tumour along with a margin of surrounding liver. Operators in the trial tailored power delivery between 40 and 100 watts over sessions lasting four to fifteen minutes, and performed track ablation as the probe was withdrawn to reduce the risk of needle-track seeding. The technique is well established, supported by robust evidence for durable local control, and is generally preferred over other thermal methods when technically feasible. Yet it remains an invasive procedure, carrying the procedural risks of anaesthesia, probe placement, and in some cases laparoscopic or open surgical access.

Stereotactic body radiotherapy, or SBRT, takes an entirely different route to the same goal. Instead of physically entering the body, it delivers very high doses of precisely sculpted radiation in a handful of fractions, exploiting steep dose gradients to destroy the tumour while sparing healthy tissue. In LAVA-CRLM, the preferred regimen was 45 Gy delivered in three fractions over one week, prescribed so that the gross tumour received a biologically effective dose exceeding 173 Gy, well above thresholds previously associated with high local control rates. Most patients in the radiotherapy arm were treated on an integrated magnetic resonance imaging linear accelerator, an MR-linac, which allows clinicians to visualise soft tissue in real time and adapt the treatment plan daily as anatomy shifts. The remaining patients received conventional linac treatment with cone-beam CT guidance and fiducial tracking. Either way, the entire process is non-invasive and requires no general anaesthesia.

Between January 2019 and December 2024, the Danish team enrolled 100 patients with one to three liver metastases smaller than 4.0 centimetres, each judged suitable for both treatments by a hepatopancreatobiliary multidisciplinary team. Participants were randomly assigned in equal numbers to MWA or SBRT. After exclusions for screening failures, disease progression, or protocol deviations, the modified intention-to-treat population comprised 92 patients, 47 treated with microwave ablation and 45 with radiotherapy. The trial’s primary endpoint was freedom from local progression, meaning the treated lesion itself remained controlled, assessed after at least one year of follow-up by a radiologist blinded to which treatment each patient had received. New lesions elsewhere were tracked separately and did not count as local failures.

The results on local control were essentially a statistical tie. With a median follow-up of roughly three and a half years, local progression occurred in 33 percent of the SBRT group and 36 percent of the MWA group. Estimated one-year freedom from local progression was 83.0 percent with radiotherapy and 77.7 percent with ablation, a difference the investigators described as showing no evidence of a separation between groups, with a hazard ratio of 0.87 and a confidence interval spanning well below and above unity. Per-protocol analyses, restricted to patients who received their assigned treatment exactly as planned, told the same story. Overall survival likewise showed no meaningful difference: three-year survival was estimated at 71.5 percent after SBRT and 63.3 percent after MWA. The trial was explicitly not powered to prove equivalence, so the wide confidence intervals leave room for clinically relevant differences, but the point estimates are remarkably close for two technologies that could hardly be more different in execution.

Safety told a sharper story. During treatment and the first month afterwards, any-grade toxicity affected 38 percent of radiotherapy patients compared with 71 percent of ablation patients. More importantly, grade 2 or higher treatment-related toxicity occurred in just 3 percent of the SBRT group versus 25 percent of the MWA group, and all grade 3 or higher treatment-related events, affecting 8 percent of ablation patients, occurred in the MWA arm. The trial also recorded one treatment-related death: a 74-year-old patient developed hepatic necrosis with capsular perforation two days after percutaneous microwave ablation and died on the day of emergency surgery. Liver pain was by far the most common complaint in the ablation group, affecting 69 percent of patients during treatment, while fatigue dominated in the radiotherapy group. The investigators attribute the more favourable safety profile of SBRT to its non-invasive delivery, which avoids the procedural risks inherent in probe placement and anaesthesia, though they caution the trial was not formally powered for toxicity comparisons.

Quality of life, measured with the EORTC QLQ-C30 questionnaire on 441 completed assessments from 98 percent of participants, showed no difference between the groups over time. The authors suggest this may reflect the dominant influence of disease progression and systemic chemotherapy on long-term wellbeing, which can drown out differences attributable to the local treatment itself. They also note a subtlety in the biology: KRAS-mutated tumours, which some evidence links to poorer local control after radiation, were numerically more frequent in the ablation group, and the trial lacked systematic molecular profiling, a limitation when interpreting the local control estimates. Tumour genetics, including KRAS and TP53 alterations, is an emerging frontier in personalising the choice between ablation and radiation for liver metastases.

The implications for clinical practice are considerable. For patients with oligometastatic colorectal liver metastases of 3 centimetres or smaller, the trial supports considering SBRT alongside MWA in multidisciplinary treatment planning, with the safety data giving radiation a potential edge for lesions where both options are technically feasible. The ability to deliver SBRT fully non-invasively, particularly with MR-guided adaptive technology that tracks tumour motion and adjusts the plan daily, may expand options for patients who cannot tolerate anaesthesia or whose lesions sit near radiosensitive structures. At the same time, ablation retains advantages of its own, including shorter overall treatment time and a single-session approach that some patients prefer over the repeated hospital visits and breath-hold manoeuvres that MR-guided radiotherapy can entail. Individualised selection based on tumour location, size, patient fitness, and institutional expertise remains essential.

The Danish investigators are careful about the limits of their evidence. This was a phase II study in a single national network, designed to detect large differences rather than establish equivalence, and all treated metastases were 3.0 centimetres or smaller despite eligibility extending to 4.0 centimetres. Larger confirmatory trials are needed, and the ongoing COLLISION-XL study is expected to address the question for intermediate-sized lesions between 3 and 5 centimetres. Still, the trial marks a genuine milestone: the first randomised evidence that a beam of precisely focused radiation can match a probe burning tumours from the inside, while sending dramatically fewer patients to hospital with severe complications. For a patient population in which every treatment decision carries curative stakes, that is a finding worth paying attention to.

Subject of Research: A randomised phase II trial comparing microwave ablation and stereotactic body radiotherapy for oligometastatic colorectal liver metastases

Article Title: Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial

Article References: Risumlund, S. L., Stick, L. B., Appelt, A., Vogelius, I. R., Nyhuus, B., Schultz, N. A., Penninga, L., van Overeem Felter, M., Josipovic, M., & Larsen, P. N. (2026). Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial. The Lancet Regional Health – Europe, 71, Article 101879. https://doi.org/10.1016/j.lanepe.2026.101879

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101879

Keywords: colorectal cancer, liver metastases, microwave ablation, stereotactic body radiotherapy, oligometastatic disease, randomised trial, local control, treatment toxicity, MR-linac, interventional oncology, radiation oncology, phase II trial

The study, led by Ertugrul Senturk and Petek Erpolat of Gazi University Faculty of Medicine in Ankara, was designed to address a persistent evidence gap. Spinal ependymomas account for a substantial share of intramedullary spinal cord tumors in adults, yet no randomized trial has ever defined the optimal adjuvant strategy, and guidelines from the European Association of Neuro-Oncology acknowledge that recommendations for radiotherapy after subtotal resection rest on limited retrospective data. The TROD investigators restricted their analysis to adults aged 18 or older with histologically confirmed World Health Organization Grade 2 or Grade 3 tumors, excluding Grade 1 lesions such as myxopapillary ependymomas and any patient whose radiotherapy began more than six months after surgery, in order to create a analytically coherent cohort in which the timing question could be examined cleanly.

The methodological backbone of the study was conventional but rigorous. Clinical outcomes were estimated with Kaplan-Meier survival analysis, and prognostic factors were tested in multivariate Cox regression models, allowing the investigators to separate the independent contribution of each variable from the confounding influence of the others. Endpoints included local control, disease-free survival, progression-free survival, and overall survival, with local failure defined according to modern neuro-oncology response assessment criteria. With a median follow-up of 7.9 years in the Grade 2 cohort, the dataset offers something genuinely rare in this disease: a decade-scale view of what happens after adjuvant irradiation.

The dominant message from the Grade 2 cohort, which comprised 37 of the 45 patients, is that the extent of surgical resection remains the primary determinant of disease control. Gross total resection was achieved in 43.2 percent of these patients, and the results in that group were extraordinary: not a single local failure occurred, translating into 100 percent ten-year local control and disease-free survival. Among patients whose tumors were only subtotally resected, by contrast, 41.2 percent eventually experienced local failure, with five- and ten-year disease-free survival of 63.9 percent and 54.7 percent respectively, a difference that reached statistical significance at p = 0.006. In other words, even in an era when adjuvant radiotherapy is available, nothing the radiation oncologist delivers fully substitutes for a complete surgical excision when it can be achieved safely.

Yet the story is not simply one of surgery versus radiation. Despite the dramatic difference in local control, overall survival was statistically indistinguishable between the two resection groups, with ten-year overall survival of 88.9 percent after gross total resection versus 74.3 percent after subtotal resection, a difference that failed to reach significance at p = 0.70. This divergence between local control and survival underscores a clinical reality familiar to neuro-oncologists: spinal ependymomas often recur locally and slowly, and salvage treatment can extend life even when the initial disease control is imperfect. It also suggests that adjuvant radiotherapy, delivered to patients with residual disease, does meaningful work in suppressing local regrowth even if the ultimate survival benefit is harder to demonstrate in a cohort of this size.

The most consequential finding, however, concerns timing. Among non-GTR patients who had no evidence of tumor dissemination at the start, a surgery-to-radiotherapy interval exceeding 1.5 months emerged as the sole independent predictor of early recurrence, with the enormous hazard ratios noted above reaching significance at p = 0.04 for both disease-free and progression-free survival. The authors conclude that early adjuvant radiotherapy, ideally initiated within about six weeks of surgery, should be regarded as a critical management strategy for patients with residual Grade 2 disease. Because this was a retrospective analysis, the result cannot prove causation in the way a randomized trial could, and patients referred late for radiotherapy may differ in ways the models cannot fully capture. Even so, a signal this strong, in the largest direction imaginable, gives treating physicians a concrete, actionable benchmark in a field that has operated largely on intuition.

The study also clarified which patients face the steepest odds regardless of treatment. Younger age at diagnosis and the presence of baseline spinal dissemination were both independent adverse prognostic factors for progression and mortality. For patients who presented with spinal dissemination at the outset, the progression rate reached 60 percent and median overall survival collapsed to just 15.2 months, a sobering figure that illustrates how quickly this disease can shift from an indolent, surgically manageable problem to a disseminated, life-threatening one. These findings argue for careful baseline neuraxis imaging and heightened surveillance in any patient whose tumor has already seeded the cerebrospinal fluid pathways.

Grade 3, or anaplastic, ependymomas behaved very differently. In this small subgroup, five-year local control, progression-free survival, and overall survival were 56.3 percent, 41.7 percent, and 75.0 percent respectively, and 62.5 percent of patients progressed. Interestingly, gross total resection did achieve complete local control even in these aggressive tumors, but distant metastasis remained the dominant pattern of failure, occurring in 60 percent of progressive cases. This dissociation between local and distant control carries an important implication: for anaplastic tumors, excellent local therapy is not enough, and the field may need to think in terms of systemic or craniospinal strategies to address the risk of dissemination, an area where current evidence remains thin and clinical trials are urgently needed.

The technical details of the radiation itself matter as well, even though the published abstract centers on timing and extent of resection. Modern practices, including image-guided and increasingly stereotactic approaches to the spine, allow high conformal doses to be delivered to residual tumor while sparing the exquisitely radiation-sensitive spinal cord, and the study’s data collection aligned with standard toxicity grading frameworks to capture treatment-related harm. The authors report no funding sources and no competing interests, and the dataset is available from the corresponding author upon reasonable request, inviting external validation of their findings.

What should patients and clinicians take away from this work? First, gross total resection remains the gold standard, and every effort should be made to achieve it when it can be done without unacceptable neurological risk, an aim increasingly supported by intraoperative neuromonitoring. Second, when residual disease is left behind, adjuvant radiotherapy demonstrably provides effective local control in Grade 2 tumors, and delaying it beyond roughly six weeks appears to carry a substantial and measurable cost in recurrence risk. Third, Grade 3 histology and initial spinal dissemination mark patients for intensified surveillance and, plausibly, for future trials of more aggressive combined-modality therapy. In a rare disease where no single institution will ever accumulate enough patients to answer these questions alone, the multicenter TROD model itself deserves credit: by pooling nearly three decades of experience across ten centers, the group has produced one of the clearest evidence-based guides yet for a treatment dilemma that neurosurgeons and radiation oncologists confront every week.

Subject of Research: Long-term outcomes of adjuvant radiotherapy in adult WHO Grade 2 and 3 spinal ependymomas

Article Title: Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

Article References: Senturk, E., Erpolat, P., Kamer, S., Yücel, B., Barış, B. Ş., Bayatfard, P., Atasoy, B., Çetinayak, H. O., Atasever Akkaş, E., Baltalarlı, P. B., & Delikgöz Soykut, E. (2026). Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005). Journal of Neuro-Oncology, 179(2), Article 77. https://doi.org/10.1007/s11060-026-05793-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05793-z

Keywords: spinal ependymoma, adjuvant radiotherapy, gross total resection, subtotal resection, local control, disease-free survival, progression-free survival, overall survival, anaplastic ependymoma, spinal dissemination, recurrence timing, neuro-oncology